• Capricor Therapeutics (CAPR) Downgraded to “Sell” at Zacks Investment Research

    Zacks Investment Research lowered shares of Capricor Therapeutics (NASDAQ:CAPR) from a hold rating to a sell rating in a research report report …

    Read More
  • 0 0